Mustafa Erman

Biyografi:

2016-… Klinik Araştırmalar Birimi Sorumlusu (Hacettepe Üniversitesi Hastaneleri)

2020-2023 – Müdür Yardımcısı (Hacettepe Üniversitesi Kanser Enstitüsü)

2016 – Profesör Doktor (Hacettepe Üniversitesi Kanser Enstitüsü)

2005 – Doçent Doktor (Hacettepe Üniversitesi Kanser Enstitüsü)

2001 – Tıbbi Onkoloji Uzmanı

1998 – İç Hastalıkları Uzmanı

1992 – Tıp Doktoru

1. Baseline vitamin D status and clinical outcomes in advanced non-small cell lung cancer patients treated with nivolumabAğdaş G., Bayir D., Şahin E., Cengiz M., GÜVEN D. C., Demir M. S., et al.Scientific Reports, cilt.16, sa.1, 2026 (SCI-Expanded, Scopus)
2. The prognostic significance of early changes in the lung immune prognostic index in patients treated with immunotherapy for advanced-stage lung cancerCengiz M., BOZKURT O., NURANSOY CENGİZ A., İNANÇ M., ÖZKAN M., Mutlu Ozkan E., et al.Discover Oncology, cilt.17, sa.1, 2026 (SCI-Expanded, Scopus)
3. Comparison of flat-dose versus weight-based dose nivolumab treatment in NSCLC patientsCengiz M., BOZKURT O., Cengiz A. N., GÜVEN D. C., Sahin E., Ozkan E. M., et al.Scientific Reports, cilt.16, sa.1, 2026 (SCI-Expanded, Scopus)
4. Baseline serum folic acid as a prognostic biomarker in metastatic renal cell carcinoma treated with targeted therapyAKTEPE O. H., Izgor R. B., ULAŞLI T., ÜNEK İ. T., ATAĞ AKYÜREK E., SEMİZ H. S., et al.Discover Oncology, cilt.17, sa.1, 2026 (SCI-Expanded, Scopus)
5. Prognostic value of the Scottish Inflammatory Prognostic Score in advanced NSCLC treated with second-line nivolumabKÖLEMEN E., UYGUN K., ÇABUK D., ERMAN M., Kılıçkap S., KÖŞECİ T., et al.Discover Oncology, cilt.17, sa.1, 2026 (SCI-Expanded, Scopus)
6. Baseline and three-month De Ritis ratio and gamma-glutamyltransferase as prognostic biomarkers in metastatic renal cell carcinoma treated with targeted therapyAKTEPE O. H., ULAŞLI T., ÜNEK İ. T., ATAĞ AKYÜREK E., SEMİZ H. S., KARAOĞLU A., et al.Scientific Reports, cilt.16, sa.1, 2026 (SCI-Expanded, Scopus)
7. SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1–High, Locally Advanced, Unresectable or Metastatic Non–Small Cell Lung CancerPeters S., Herbst R., Horinouchi H., Paz-Ares L., Johnson M., Solomon B. J., et al.Journal of Clinical Oncology, cilt.44, sa.25, 2026 (SCI-Expanded, Scopus)
8. Association of Cabazitaxel Treatment Beyond 10 Cycles with Survival Outcomes in Metastatic Castration-Resistant Prostate Cancer: A Retrospective 8-Month Landmark AnalysisTaban H., AKSOY S., Evlendi Y., AKTAŞ B. Y., Aslan F., ERMAN M.Journal of Clinical Medicine, cilt.15, sa.18, 2026 (SCI-Expanded, Scopus)
9. Clinical Characteristics and Survival Outcomes of a Clinically Defined Treatment-Emergent Neuroendocrine/Aggressive-Variant Prostate Cancer Phenotype: A Retrospective StudyTaban H., AKSOY S., GÜVEN D. C., AKTAŞ B. Y., Yılmaz F., Aslan F., et al.Medicina (Lithuania), cilt.62, sa.9, 2026 (SCI-Expanded, Scopus)
10. Prognostic Value of the Modified Glasgow Prognostic Score in Patients with Metastatic Renal Cell Carcinoma Receiving Nivolumab as Second-Line Therapy: A Multicentre Retrospective Cohort StudyBiter S., BAYRAM E., KÖŞECİ T., İçli M. C., Arslan A. M., Özalp F. R., et al.Medicina (Kaunas, Lithuania), cilt.62, sa.9, 2026 (SCI-Expanded, Scopus)
11. Real-World Efficacy and Safety of Frontline Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Study and Review of the LiteratureKıkılı C. İ., Araz M., ÜRÜN Y., BAŞARAN M., Şener N., Yazar A., et al.Clinical Genitourinary Cancer, cilt.24, sa.5, 2026 (SCI-Expanded, Scopus)
12. Serum Vitamin D Levels as a Prognostic Biomarker in Patients Receiving Immune Checkpoint InhibitorsŞahi̇n T. K., BAŞ O., KAVGACI G., Güdük N., ŞİRVAN F., AKIN S., et al.Journal of Oncological Science, cilt.12, sa.1, ss.1-8, 2026 (Scopus, TRDizin)
13. Comparison of 6 cycles with 4 cycles of chemotherapy and atezolizumab in the first-line treatment of ES-SCLC: a retrospective multicenter analysisGüzel H. G., Kıvrak Salim D., Kılıçkap S., Kemal Y., Akosman C., Köseoğlu Ç., et al.Oncologist, cilt.31, sa.4, 2026 (SCI-Expanded, Scopus)
14. High AST and the presence of liver metastases may guide for the need for FDG PET in advanced prostate cancer patientsTelli T., TUNCEL M., KARABULUT E., AKSOY S., ERMAN M., AKDOĞAN B., et al.Urologic Oncology: Seminars and Original Investigations, cilt.44, sa.4, 2026 (SCI-Expanded, Scopus)
15. Survival Outcomes After irAE-Related Nivolumab Discontinuation in mNSCLC: A Multicenter StudyÇETİNKAYA YAPRAK A., Yucel M. H., Karahan L., ERSOY M., BİLİCİ A., ERMAN M., et al.Journal of Clinical Medicine, cilt.15, sa.8, 2026 (SCI-Expanded, Scopus)
16. Real-world comparison of cabozantinib and sunitinib in advanced non-clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology GroupŞahin G., Tüzün E. K., Güzel H. G., Guliyev M., Dişli A. K., YAZICI M., et al.International Journal of Cancer, cilt.158, sa.4, ss.1067-1079, 2026 (SCI-Expanded, Scopus)
17. Prognostic factors in avelumab maintenance therapy for metastatic urothelial carcinomaKapar C., Özkan O., Eylemer Mocan E., YASLIKAYA Ş., Tatlı A. M., Akdağ G., et al.Immunotherapy, 2026 (SCI-Expanded, Scopus)
18. Prognostic Significance of C-PLAN Index in Patients Treated with Immunotherapy for Non-Small-Cell Lung CancerNURANSOY CENGİZ A., BOZKURT O., Cengiz M., ÖZKAN M., İNANÇ M., KEFELİ U., et al.Journal of Clinical Medicine, cilt.15, sa.2, 2026 (SCI-Expanded, Scopus)
19. Real-world testing practices, treatment patterns, and outcomes of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor-mutated advanced/metastatic non-small cell lung cancer: An international studySamol J., Demedts I., ERMAN M., Kozlov V., Minatta J. N., Moiseenko F., et al.Cancer Treatment and Research Communications, cilt.48, 2026 (ESCI, Scopus)
20. Impact of renin–angiotensin system inhibitors on the clinical outcomes of nivolumab therapy in metastatic non–small cell lung cancerMutlu Ozkan E., Karadağ I., Sahın E., NURANSOY CENGİZ A., Cengız M., Can Guven D., et al.Expert Review of Anticancer Therapy, cilt.26, sa.7, ss.929-936, 2026 (SCI-Expanded, Scopus)
21. The lactate dehydrogenase-to-albumin ratio is a prognostic biomarker in extensive-stage small-cell lung cancerYILMAZ F., Yaşar S., Tatar O. D., Yildirim H. c., Guven D. C., TABAN H., et al.Acta Medica, cilt.56, sa.3, ss.186-198, 2025 (TRDizin)
22. Early Changes in Volumetric Body Composition Parameters Predict Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with Targeted TherapyAKTEPE O. H., ERDEMİR A. G., Yildirim E. C., Demirciler E., ULAŞLI T., GÜVEN D. C., et al.JOURNAL OF CLINICAL MEDICINE, cilt.14, sa.9, 2025 (SCI-Expanded, Scopus)
23. Comparative Analysis of Prognostic Potential of Pretreatment Blood-Based Biomarkers in Metastatic Bladder Cancer: Modified Glasgow Prognostic ScoreKUŞ F., GÜVEN D. C., YILDIRIM H. Ç., Chalabiyev E., Koc I., Tatar O. D., et al.JOURNAL OF CLINICAL MEDICINE, cilt.14, sa.6, 2025 (SCI-Expanded, Scopus)
24. Efficacy and Clinical Outcomes of Crizotinib in Patients with ROS1-Rearranged NSCLC: A Multicenter StudyTopal A., Akdag G., Yildirim S., Kinikoglu O., Isik D., Yildirim G., et al.MEDICINA-LITHUANIA, cilt.61, sa.3, 2025 (SCI-Expanded, Scopus)
25. Avelumab maintenance in patients with metastatic urothelial carcinoma in a real-life expanded-access program (EAP).Tural D., Ozkan O., YASLIKAYA Ş., TATLI A. M., Akdag G., Demir H., et al.JOURNAL OF CLINICAL ONCOLOGY, sa.5_SUPPL, 2025 (SCI-Expanded, Scopus)
26. The association between HALP score and survival in patients treated with immune checkpoint inhibitorsŞAHİN T. K., GÜVEN D. C., Durukan M., BAŞ O., KAYGUSUZ Y., ARIK Z., et al.EXPERT REVIEW OF ANTICANCER THERAPY, cilt.25, sa.1, ss.81-89, 2025 (SCI-Expanded, Scopus)
27. Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinomaYildirim H. C., BAYRAM E., Chalabiyev E., Majidova N., Avci T., Guzel H. G., et al.JOURNAL OF CHEMOTHERAPY, cilt.37, sa.6, ss.551-562, 2025 (SCI-Expanded, Scopus)
28. The association between blood sodium levels and survival in patients treated with immune checkpoint inhibitorsŞAHİN T. K., GÜVEN D. C., Durukan M., KAVGACI G., KAYGUSUZ Y., ARIK Z., et al.EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, cilt.25, sa.4, ss.129-137, 2025 (SCI-Expanded, Scopus)
29. Association Between Baseline and Changes in Early Neutrophil-to-Lymphocyte Ratio on Survival in Patients with Metastatic Bladder Carcinoma Treated with ImmunotherapyDegerli E., Arslan C., Selcukbiricik F., Olmez O. F., Erdem D., Hamdard J., et al.MEDICINA-LITHUANIA, cilt.60, sa.12, 2024 (SCI-Expanded, Scopus)
30. Immune Checkpoint Blockade Therapies Efficacy and Toxicity in Patients With Impaired Renal Function in Metastatic Bladder CancerTural D., Arslan C., Selcukbiricik F., Olmez O. F., Akar E., ERMAN M., et al.CLINICAL GENITOURINARY CANCER, cilt.22, sa.6, 2024 (SCI-Expanded, Scopus)
31. Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancerYILMAZ F., YAŞAR S., Tatar O. D., Yildirim H. C., Guven D. C., AKYILDIZ A., et al.BMC CANCER, cilt.24, sa.1, 2024 (SCI-Expanded, Scopus)
32. Efficacy of Systemic Treatments in Patients With Metastatic Lung Invasive Mucinous AdenocarcinomaDemir T., Araz M., Moloney C., Hendem E., Kocak M. Z., ERMAN M., et al.CLINICAL LUNG CANCER, sa.7, 2024 (SCI-Expanded, Scopus)
33. Objective Response Rate is a Surrogate Marker for Long-Term Overall Survival in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint InhibitorsTural D., Arslan C., Selcukbiricik F., ÖLMEZ Ö. F., ERMAN M., ÜRÜN Y., et al.CLINICAL GENITOURINARY CANCER, cilt.22, sa.5, 2024 (SCI-Expanded, Scopus)
34. Impact of opioid analgesics on survival in cancer patients receiving immune checkpoint inhibitorsKAVGACI G., GÜVEN D. C., KAYGUSUZ Y., KARACA E., DİZDAR Ö., Kilickap S., et al.SUPPORTIVE CARE IN CANCER, cilt.32, sa.7, 2024 (SCI-Expanded, Scopus)
35. A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)Lara Jr P. N., Villanueva L., Ibanez C., ERMAN M., Lee J. L., Heinrich D., et al.BMC CANCER, cilt.23, sa.SUPPL 1, 2024 (SCI-Expanded, Scopus)
36. Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)YAŞAR H. A., AKTAŞ B. Y., Ucar G., SEZGİN GÖKSU S., Bilgetekin I., Cakar B., et al.Clinical Genitourinary Cancer, cilt.22, sa.3, 2024 (SCI-Expanded, Scopus)
37. A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacyKILIÇKAP S., Ozturk A., Karadurmus N., KORKMAZ T., YUMUK P. F., ÇİÇİN İ., et al.MEDICINE, cilt.103, sa.21, 2024 (SCI-Expanded, Scopus)
38. The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) studyGuven D. C., Aykan M. B., MUĞLU H., BAYRAM E., Helvaci K., DURSUN B., et al.Cancer Medicine, cilt.13, sa.1, 2024 (SCI-Expanded, Scopus)
39. Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?GÜNER G., AKTAŞ B. Y., Başal F. B., DEMİRKAZIK A., Gürsoy P., Demirci U., et al.Journal of Cancer Research and Clinical Oncology, cilt.149, sa.14, ss.13271-13277, 2023 (SCI-Expanded, Scopus)
40. Mean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with NivolumabYILDIRIM H. Ç., KUŞ F., GÜVEN D. C., Karaca E., KAYGUSUZ Y., DİZDAR Ö., et al.Journal of Immunotherapy and Precision Oncology, cilt.6, sa.4, ss.170-176, 2023 (Scopus)
41. The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitorsGÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., KAVGACI G., Aksun M. S., ERUL E., et al.Anti-Cancer Drugs, cilt.34, sa.6, ss.783-790, 2023 (SCI-Expanded, Scopus)
42. The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort studyGÜVEN D. C., Yekeduz E., Erul E., YAZGAN S. C., ŞAHİN T. K., KARATAŞ G., et al.JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, cilt.149, sa.7, ss.3599-3606, 2023 (SCI-Expanded, Scopus)
43. Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical PracticeTural D., Arslan C., Selcukbiricik F., Olmez O. F., Akar E., ERMAN M., et al.Clinical Genitourinary Cancer, cilt.21, sa.3, ss.334-341, 2023 (SCI-Expanded, Scopus)
44. Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapyGÜVEN D. C., Incesu F. G. G., YILDIRIM H. Ç., Erul E., Chalabiyev E., AKTAŞ B. Y., et al.INTERNATIONAL JOURNAL OF CANCER, cilt.152, ss.679-685, 2023 (SCI-Expanded, Scopus)
45. NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLCde Castro G., Rizvi N. A., Schmid P., Syrigos K., Martin C., Yamamoto N., et al.Journal of Thoracic Oncology, cilt.18, sa.1, ss.106-119, 2023 (SCI-Expanded, Scopus)
46. Blood Based Biomarkers as Predictive Factors for Hyperprogressive DiseaseYILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., et al.JOURNAL OF CLINICAL MEDICINE, cilt.11, sa.17, 2022 (SCI-Expanded, Scopus)
47. The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with ImmunotherapyGÜVEN D. C., ŞAHİN T. K., Erul E., ÇAKIR İ. Y., ÜÇGÜL E., YILDIRIM H. Ç., et al.JOURNAL OF CLINICAL MEDICINE, cilt.11, sa.15, 2022 (SCI-Expanded, Scopus)
48. The burden of polypharmacy and drug-drug interactions in older cancer patients treated with immunotherapyGÜVEN D. C., KAVGACI G., AKTEPE O. H., YILDIRIM H. H., ŞAHİN T. K., AKSOY S., et al.JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.28, sa.4, ss.785-793, 2022 (SCI-Expanded, Scopus)
49. Effect of docetaxel (D) use on survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with novel hormonal therapies (NHTs): A meta-analysis.Guven D. C., Sayegh N., Tripathi N., Erman M., Agarwal N., Swami U.JOURNAL OF CLINICAL ONCOLOGY, cilt.40, sa.16, 2022 (SCI-Expanded, Scopus)
50. Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)& nbsp;Levy B., Barlesi F., Paz-Ares L., Bennouna J., ERMAN M., Felip E., et al.LUNG CANCER, cilt.166, ss.107-113, 2022 (SCI-Expanded, Scopus)
51. Response to first-line chemotherapy regimen is associated with efficacy of immune checkpoint blockade therapies in patients with metastatic urothelial carcinomaTural D., Selcukbiricik F., Olmez O. F., Sumbul A. T., ERMAN M., COŞKUN H. Ş., et al.INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, cilt.27, sa.3, ss.585-591, 2022 (SCI-Expanded, Scopus)
52. Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell CarcinomaIsmayilov R., AKTEPE O. H., Sardarova K., LEBLEBİCİ C. B., ERMAN M.EURASIAN JOURNAL OF MEDICINE, cilt.54, sa.1, ss.77-79, 2022 (ESCI, Scopus, TRDizin)
53. Long-term outcome and safety in patients treated with immune checkpoint blockade therapies for urothelial carcinoma: Experience from real-world clinical practice.Tural D., Arslan C., Selcukbiricik F., Olmez O. F., Erman M., Urun Y., et al.JOURNAL OF CLINICAL ONCOLOGY, cilt.40, sa.6, 2022 (SCI-Expanded, Scopus)
54. Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving ImmunotherapyYILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., et al.EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, cilt.6, sa.1, ss.59-63, 2022 (ESCI, TRDizin)
55. The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center studyGÜVEN D. C., Acar R., Yekeduz E., Bilgetekin I., Baytemur N. K., EROL C., et al.CURRENT PROBLEMS IN CANCER, cilt.45, sa.6, 2021 (SCI-Expanded, Scopus)
56. The Predictive Value of Red Blood Cell Distribution Width for Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Treated with Targeted TherapyAKTEPE O. H., GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇELİKTEN B., Yeter H. H., et al.NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, cilt.73, sa.10, ss.1957-1963, 2021 (SCI-Expanded, Scopus)
57. Should Protocols Specific to Histologic Subtypes Be Applied in the Follow-Up of NSCLC?ARIK Z., ERMAN M.JOURNAL OF THORACIC ONCOLOGY, cilt.16, sa.10, 2021 (SCI-Expanded, Scopus)
58. Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life ExperiencesTural D., Olmez O. F., Sumbul A. T., ARTAÇ M., Ozhan N., Akar E., et al.EUROPEAN UROLOGY FOCUS, cilt.7, sa.5, ss.1061-1066, 2021 (SCI-Expanded, Scopus)
59. Lower prognostic nutritional index is associated with poorer survival in patients receiving immune-checkpoint inhibitorsGÜVEN D. C., AKTEPE O. H., TABAN H., AKTAŞ B. Y., GÜNER G., YILDIRIM H. H., et al.BIOMARKERS IN MEDICINE, cilt.15, sa.13, ss.1123-1130, 2021 (SCI-Expanded, Scopus)
60. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapyGÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., et al.SUPPORTIVE CARE IN CANCER, cilt.29, sa.9, ss.5417-5423, 2021 (SCI-Expanded, Scopus)

All 117 on AVESİS →

1. Efficacy of systemic treatments in patients with metastatic lung invasive mucinous adenocarcinomaDemir T., Araz M., Hendem E., Kocak M. Z., Erman M., Bas O., et al.Special Clinical Science Symposia, ELECTR NETWORK, 29 Mayıs 2024, (Özet Bildiri)
2. Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experienceTural D., Olmez O. F., Sumbul A. T., Artac M., Ozhan N., Akar E., et al.Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San-Francisco, Kostarika, 13 - 15 Şubat 2020, cilt.38, (Özet Bildiri)
3. İki olgu nedeniyle Nivolimumaba bağlı akciğer toksisitesiBABAOĞLU E., SARINÇ ULAŞLI S., KÖKSAL D., ERMAN M., BARIŞTA İ.Ulusal Akciğer Sağlığı Kongresi, Türkiye, 14 - 18 Mart 2018, (Özet Bildiri)
4. Brain Tissue Follow-up Using Dynamic Susceptibility Contrast-Enhanced and Dynamic Contrast-Enhanced Perfusion Magnetic Resonance Imaging on Lesions Categorized by Apparent Diffusion Coefficient Values in GlioblastomaOMAY B., ARDALI S., MUT AŞKUN M., KILIÇKAP S., ERMAN M., KARLI OĞUZ H. K.Radiology Society of North America, 26 Kasım - 01 Aralık 2017, (Özet Bildiri)
5. Efficiency of a psychoeducational Intervention for smoking cessation in a specialized cessation clinicYÜCE D., KAMIŞLI S., KÜÇÜKÇOBAN ş., HAYRAN K. M., KILIÇKAP S., ÇELİK İ., et al.2017 World Congress of Psycho-Oncology, 14 - 18 Ağustos 2017, (Özet Bildiri)
6. Tirozin Kinaz İnhibitörü Kaynaklı Tiroid Fonksiyon BozukluğuTECEN K., ÖZDEMİR N., KARA E., EKİNCİOĞLU A., DEMİRKAN S. K., ERMAN M., et al.18. ULUSAL İÇ HASTALIKLARI KONGRESİ, Türkiye, 12 - 16 Ekim 2016, (Özet Bildiri)
7. Anti TNF treatment may induce EBV reactivation in RA patients A clue for increased risk of lymphomaTOKGÖZOĞLU S. L., ERTENLİ A. İ., KALYONCU U., ALP A., KARADAĞ Ö., ERMAN M., et al.Annual European Congress of Rheumatology (EULAR 2006), 21 - 24 Haziran 2006, (Tam Metin Bildiri)
8. Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphomaKilickap S., Yavuz B., Aksoy S., Sahiner L., Harputluoglu H., Dincer M., et al.30th Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.202, (Özet Bildiri)
9. An open study of clarithromycin in the treatment of pneumonia due to Streptococcus pneumoniaeHAYRAN M., Erman M., GUR D., Akova M., Unal S.3rd International Conference on the Macrolides, Azalides, and Streptogramins, Lisbon, Portekiz, 24 - 26 Ocak 1996, cilt.21, ss.429-431, (Tam Metin Bildiri)
10. BİR ÜNİVERSİTENİN SİGARA BIRAKMA ÜNİTESİNE BAŞVURANLARIN ÖZELLİKLERİ VE SİGARA BIRAKMA OLASILIKLARIŞENGELEN M., ÇELİK İ., ERMAN M., Tezcan S., YÜCE D., Kamışlı S., et al.
11. TRANSCULTURAL ADAPTATION OF EORTC-QLQ-CR29 SCALE INTO TURKISH, AND ASSESSMENT OF VALIDITY ANDRELIABILITY IN TURKISH PATIENTS WITH COLORECTAL CANCERHAYRAN K. M., YÜCE D., KILIÇKAP S., houssein b., ERMAN M., DİZDAR Ö., et al.
12. EFFECTS OF CANCER TYPES ON LOCAL AND OUT-OF-CITY ADMISSIONS FOR MEDICAL CAREHAYRAN K. M., YÜCE D., KILIÇKAP S., DİZDAR Ö., houssein b., ERMAN M., et al.
13. Metastatik kastrasyona dirençli prostat kanser hastalarında kabazitakselin güvenlik verileri: Kabazitaksel Türkiye insani amaçlı ilaca erişim programı sonuçlarıBAVBEK S., BAŞARAN M., ÖZEN A. H., ERMAN M., ÖZDOĞAN M., ÖZGÜROĞLU M., et al.
14. Smoker relatives of inpatients: A reasonable but heterogeneous target population for smoking cessation programAKTAŞ B. Y., HOUSSEİN b., YÜCE D., DİZDAR Ö., KILIÇKAP S., ERMAN M., et al.
15. Using geographical information systems to describe quality of life as a function of distance in cancer patientsHAYRAN K. M., ERMAN M., KILIÇKAP S., DİZDAR Ö., YÜCE D., HÜSEYİN B., et al.
16. Factors that affect the suitability of cancer patients for clinical drug trials in Turkey: Final analysis of a multicenter study.Erman M., Kilickap S., Ekinci A. S., Koca S., Ata A., Besen A., et al.
17. Temporal changes in the survival of metastatic renal cell cancer patients and the impact of targeted agents: Single center experienceErman M., Arik Z., Kilickap S., Bilen C. Y., Yazici S., Akdogan B., et al.

1. Kastrasyona dirençli prostat kanseri tedavisiERMAN M., ARIK Z.Üroonkoloji Kitabı, , Editör, Nobel, 2018